Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody

• US 9,403,902 B2
• Filed: 10/03/2008
• Issued: 08/02/2016
• Est. Priority Date: 10/05/2007
• Status: Active Grant

• Current Assignee: AC Immune SA, Genentech, Inc. (Roche Holding AG)
• Original Assignee: AC Immune SA, Genentech, Inc. (Roche Holding AG)
• Inventors: Pfeifer, Andrea, Pihlgren, Maria, Muhs, Andreas, Watts, Ryan
• Primary Examiner(s): BALLARD, KIMBERLY
• Application Number:
  US12/681,696
• Publication Number:
  US 20100291097A1
• Time in Patent Office: 2,860 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]

Abstract

The present invention provides methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of amyloid-beta proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly those ocular diseases associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system.

Claims

1. A method for protection against, treating or alleviating one or more of the effects of an ocular disease associated with amyloid-beta-related pathological abnormalities or changes in the tissues of the visual system in a subject comprising administering intraocularly or intravitreally to the subject a pharmaceutical composition comprising an effective amount of an antibody which binds amyloid-beta, wherein the antibody comprises:

(i) a light chain variable region comprising a light chain complementarity determining region (CDR)1 comprising the amino acid sequence of SEQ ID NO;

9, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO;

10, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO;

11; and

(ii) a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO;

12, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO;

13, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO;

14,

and wherein the ocular disease is cortical visual deficits or cataract.

2. The method of claim 1, wherein the subject is a mammal.

3. The method of claim 2, wherein the mammal is a human.

4. The method of claim 1, wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:

7.

5. The method of claim 1, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:

8.

6. The method of claim 1, wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:

7, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO;

8.

7. The method of claim 1, wherein the antibody is a monoclonal, chimeric, single chain, bispecific or bi-effective, simianized, or humanized antibody or an active fragment thereof.

8. The method of claim 1, wherein the ocular disease is cataract.

9. The method of claim 1, wherein the ocular disease is cortical visual deficits.